Real-world data validation of the PurIST pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implications

Stephane Wenric, James M. Davison, John Guittar, Gregory M. Mayhew, Kirk D. Beebe, Yun E. Wang, Amrita A. Iyer, Hyunseok P. Kang, Michael V. Milburn, Vincent Chung, Tanios Bekaii-Saab, Charles M. Perou
doi: https://doi.org/10.1101/2023.02.23.23286356

Article Information

doi 
https://doi.org/10.1101/2023.02.23.23286356
History 
  • February 24, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Stephane Wenric1,*,
  2. James M. Davison2,
  3. John Guittar1,
  4. Gregory M. Mayhew2,
  5. Kirk D. Beebe2,
  6. Yun E. Wang1,
  7. Amrita A. Iyer1,
  8. Hyunseok P. Kang1,
  9. Michael V. Milburn2,
  10. Vincent Chung3,
  11. Tanios Bekaii-Saab4 and
  12. Charles M. Perou5
  1. 1Tempus Labs, Chicago, IL
  2. 2GeneCentric Therapeutics, Durham, NC
  3. 3City of Hope, Duarte, CA
  4. 4Mayo Clinic, Phoenix, AZ
  5. 5University of North Carolina at Chapel Hill, Chapel Hill, NC
  1. ↵*Corresponding author; email: stephane.wenric{at}tempus.com
Back to top
Posted February 24, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Real-world data validation of the PurIST pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implications
Stephane Wenric, James M. Davison, John Guittar, Gregory M. Mayhew, Kirk D. Beebe, Yun E. Wang, Amrita A. Iyer, Hyunseok P. Kang, Michael V. Milburn, Vincent Chung, Tanios Bekaii-Saab, Charles M. Perou
medRxiv 2023.02.23.23286356; doi: https://doi.org/10.1101/2023.02.23.23286356
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area